Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat bridging to PEA in operable CTEPH
NCT03273257Phase 2Terminated
- Sponsor
- International CTEPH Association
- Start
- Aug 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Riociguat with Placebo (2 arms). Primary endpoint: Pulmonary Vascular Resistance at 90 days. Started Aug 2018; status: terminated.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT03273257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03273257.